Results 61 to 70 of about 2,265,539 (159)

Taiwan Consensus for the Management of Cardiovascular Risks and Complications in Patients with Prostate Cancer. [PDF]

Acta Cardiol Sin
Chang WT, Hong JH, Chen DY, Huang CY, Chen YC, Cha TL, Wu YW, Lin TP, Cheng KH, Chiang PJ, Hung CL, Wang SS, Wang WH, Shao IH, Liao JN, Hung SC, Lin HJ, Huang SP, Liu PY, Huang KH, Wang TD, Lin JT, Li YH, Wu HC, Pang JS, Chen WJ.   +25 more
europepmc   +1 more source

Thymus Degeneration in Women and the Influence of Female Sexual Hormones on Thymic Epithelial Cells. [PDF]

Int J Mol Sci
Zhou M, Shu Y, Gao J.
europepmc   +1 more source

Testosterone castration levels in patients with prostate cancer: Is there a difference between GnRH agonist and GnRH antagonist? Primary results of an open-label randomized control study. [PDF]

Investig Clin Urol, 2023
Mytilekas VK, Papaefstathiou E, Koukourikis P, Ouzounidis X, Kazantzidis S, Hatzimouratidis K.   +5 more
europepmc   +1 more source

A retrospective cohort study assessing medication coverage in patients with prostate cancer prescribed luteinizing hormone releasing hormone (LHRH) agonists in England. [PDF]

PLoS One
Sayers I, Joao Carvalho S, Davidson J, Elster N, Heer R, Raja M, Higgs K, Nolan A, Sassmann J.   +8 more
europepmc   +1 more source

Use of Relugolix for the Prevention of Impending Oliguria and Progressive Renal Failure in a Suspected Case of Prostate Carcinoma. [PDF]

Cureus
Kumar P, Prem P, Raut A, Ahmad S, Singh S.   +4 more
europepmc   +1 more source

Recent Advances in Augmenting the Therapeutic Efficacy of Peptide-Drug Conjugates. [PDF]

J Med Chem
Ma J, Wang X, Hu Y, Ma J, Ma Y, Chen H, Han Z.   +6 more
europepmc   +1 more source

Luteinizing Hormone-Releasing Hormone (LHRH)-Conjugated Cancer Drug Delivery from Magnetite Nanoparticle-Modified Microporous Poly-Di-Methyl-Siloxane (PDMS) Systems for the Targeted Treatment of Triple Negative Breast Cancer Cells. [PDF]

J Funct Biomater
Eluu SC, Obayemi JD, Yiporo D, Salifu AA, Oko AO, Onwudiwe K, Aina T, Oparah JC, Ezeala CC, Etinosa PO, Osafo SA, Ugwu MC, Esimone CO, Soboyejo WO.   +13 more
europepmc   +1 more source

Advancements and limitations in traditional anti-cancer therapies: a comprehensive review of surgery, chemotherapy, radiation therapy, and hormonal therapy. [PDF]

Discov Oncol
Zafar A, Khatoon S, Khan MJ, Abu J, Naeem A.   +4 more
europepmc   +1 more source

Peptide based vesicles for cancer immunotherapy: design, construction and applications. [PDF]

Front Immunol
Yu Y, Lyu J, Muhadaisi Y, Shi C, Wang D.
europepmc   +1 more source

Risk factors for early recurrence in patients with hormone receptor-positive, HER2-negative breast cancer: a retrospective cohort study in Japan (WJOG15721B). [PDF]

Breast Cancer
Watanuki R, Sakai H, Takehara Y, Yoshida A, Hayashi N, Ozaki Y, Kataoka A, Uehiro N, Kamio H, Onishi M, Fushimi A, Ikeno T, Wakabayashi M, Iida M, Kawaguchi T, Takano T.   +15 more
europepmc   +1 more source